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ORIGINAL ARTICLE
GST Theta null genotype is associated with an
increased risk for ulcerative colitis: a case–control
study and meta-analysis of GST Mu and GST
Theta polymorphisms in inflammatory bowel
disease
Mark MTJ Broekman, Caro Bos, Rene´ HM te Morsche, Frank Hoentjen, Hennie MJ Roelofs,
Wilbert HM Peters, Geert JA Wanten and Dirk J de Jong
Glutathione S-transferases (GSTs) are important in the detoxification of many compounds, including reactive oxygen species.
Polymorphisms in GSTs resulting in a decreased enzyme activity might enhance the risk for inflammatory bowel disease by
eliciting a state of oxidative stress. Previous case–control studies showed divergent results and were frequently limited in
sample size; therefore we conducted a meta-analysis including results from our case–control study. For the case–control study,
we genotyped 552 patients with Crohn’s disease (CD), 223 patients with ulcerative colitis (UC) and 972 healthy controls by
PCR for functional deletions in GST Mu and GST Theta. Both were not analyzed in recent genome-wide association studies. For
the meta-analysis, PubMed, EMBASE and Web of Science were searched. In this meta-analysis, we show an enhanced
susceptibility for UC in individuals with the GSTT1null genotype (odds ratio (OR) 2.27, 95% confidence interval (CI) 1.31–
3.92). In our case–control study, a reduced risk for CD was seen with the GSTT1null genotype (OR 0.58, 95% CI 0.43–0.77);
however, pooled analysis showed an OR of 1.67, 95% CI 0.81–3.45. In this meta-analysis, we showed an increased risk for
UC in individuals with the GSTT1null genotype.
Journal of Human Genetics advance online publication, 4 September 2014; doi:10.1038/jhg.2014.77
INTRODUCTION
Genetic factors become more and more recognized as contributing
factors in the development of inflammatory bowel disease (IBD).
Recent genome-wide association studies (GWASs) generated a large
set of candidate genes for Crohn’s disease (CD), ulcerative colitis
(UC) and for IBD in general.1
Glutathione S-transferases (GSTs) are a family of enzymes that have
an essential role within cells, including the conjugation and detox-
ification of toxic or carcinogenic compounds, such as reactive oxygen
species (ROS).2 Polymorphisms in GSTs can lead to a decreased
enzyme function, and an inadequate detoxification of ROS might
modulate the susceptibility for IBD.3 Biopsies of colonic mucosa of
IBD patients showed an increased ROS production compared with
healthy controls.4 A reduced enzyme function of GSTs and therewith
impaired scavenging of ROS can contribute to a state of oxidative
stress, which can trigger the onset of IBD.5,6
Human GSTs can be divided in four main classes, GST Alpha
(GSTA), GST Mu (GSTM1), GST Pi (GSTP1) and GST Theta
(GSTT1). For GSTP1, several polymorphisms have been described,
with GSTP1 105 (rs1695) and GSTP1 114 (rs1138272) considered as
the most important, because these GSTP1 polymorphisms result in a
reduced enzyme function.7 Both GSTP1 105 and GSTP1 114 were not
found to be associated with UC or CD in a GWAS.1 For GSTM1,
three alleles have been described of which one, GSTM1*0, is
characterized by a gene deletion, leading to a non-functional
protein. Homozygous presence of the GSTM1*0 allele (GSTM1null)
results in no enzyme activity and is found in approximately 50% of
Caucasians and Asians.2,8 The same applies to GSTT1, where a gene
deletion (GSTT1*0 allele) is responsible for a failed protein synthesis.
The homozygous GSTT1*0 genotype, GSTT1null, which occurs in
approximately 10–20% of Caucasians and 16–64% of Asians, leads to
the absence of GSTT1 enzyme activity.2,8 The gene deletions of
GSTM1*0 or GSTT1*0 were not analyzed in GWASs,1 so evidence is
limited to case–control studies. In these studies, an association
between GSTM1*0, GSTT1*0 or a combination of these polymorph-
isms and susceptibility for CD or UC was found. However, it has to
be stressed that some studies had relatively low patient numbers, and
overall results remain inconsistent.9–12 Therefore we conducted a large
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case–control study and included our results in a meta-analysis of
studies addressing the susceptibility for CD and UC with respect to
GSTM1 and GSTT1 null polymorphisms.
MATERIALS AND METHODS
Study design and ethics
For the case–control study, IBD patients were recruited at the outpatient clinic
of the Radboud University Medical Center, Nijmegen, the Netherlands.
Healthy controls were recruited from the Nijmegen area, by advertisement in
local papers, as described earlier.13 Diagnosis of IBD was based on accepted
clinical, endoscopic, radiological and histological findings.14 The investigations
were approved by the Medical Ethical Review Committee of the Radboud
University Nijmegen Medical Center under the protocol number CWOM-nr
9804-0100.
DNA isolation and genotyping
Peripheral blood samples of IBD patients and healthy controls were collected
and genomic DNA was isolated with the ROCHE High Pure PCR template
Preparation Kit (Roche Applied Science, Mannheim, Germany). DNA was
stored at 4 1C until further use. Polymorphisms in GSTM1 and GSTT1 were
analyzed using PCR as described previously.15 The primers 50-CTGGATTGTA
GCAGATCATGC-30/50-CTCCTGATTATGACAGAAGCC-30 and 50-TCACCGG
ATCATGGCCAGCA-30/50-TTCCTTACTGGTCCTCACATCTC-30 were used
for GSTM1 and GSTT1, respectively. To detect GSTM1 and GSTT1
genotypes, melt curve analysis was applied using the Bio-Rad Precision Melt
Analysis Software version 1.0 (Bio-Rad, Hercules, CA, USA) and in this way
homozygous and heterozygous most common genotypes could be distinguished
from homozygous GSTM1*0 (null) or GSTT1*0 (null) genotypes.
Data search
The meta-analysis was conducted according to PRISMA guidelines. Articles for
the meta-analyses were retrieved by searching PubMed, EMBASE and Web of
Science on 13 October 2013 with the following search terms: GST, glutathione
S-transferase, detoxification enzymes, inflammatory bowel disease, ulcerative
colitis, and Crohn’s disease. Case–control studies examining the association of
GST polymorphisms in patients with IBD in relation to healthy controls were
included, provided that absolute numbers of genotypes of patients and
controls were given. Studies were excluded when no full text was available
or written in a language other than English, German or Dutch. In case of
overlapping data, the study with the largest number of cases was included. The
reference lists of included articles were screened for potential eligible studies.
Two researchers (MB and RM) independently extracted raw data of the
genotype distributions of GSTM1, GSTT1 and the combination of GSTM1
with GSTT1 from the included studies, and in case of inconsistency, results
were discussed until consensus was reached.
Statistical analysis
For the case–control study, baseline continuous variables were compared by
independent t-test. Categorical data between patients and healthy controls were
analyzed with the chi-squared test. Genotypes with predicted high enzyme
activity were used as reference to calculate odds ratios (OR) and 95% confidence
intervals (95% CI) with logistic regression. The combination GSTM1null and
GSTT1null was compared with all other genotypes. Analyses were conducted with
the SPSS for windows version 20.0 (SPSS Inc., Chigaco, IL, USA).
For the meta-analyses a random effect model was used to calculate pooled
ORs from studies, including results of our case–control study. ORs with 95%
CI were calculated with the Mantel–Haenszel method in Review Manager
(RevMan) version 5.2. (The Nordic Cochrane Centre, The Cochrane Colla-
boration, Copenhagen, Denmark). The P-values of significance of the ORs are
depicted in the bottom line of the corresponding forest plots. Finally,
heterogeneity was assessed with the I2 test, and publication bias was estimated
with a funnel plot.
RESULTS
Case–control study
For the case–control study, we included 552 patients with CD (mean
age 44.4 years, s.d.±13.8), 233 patients with UC (mean age 45.8
years, s.d.±13.7) and 972 healthy controls (mean age 47.2 years,
s.d.±16.6). Table 1 shows the GST genotype distribution in patients
with CD and UC in comparison with healthy controls. With the
homozygousþ heterozygous most common genotypes set as refer-
ence, the GSTM1null genotype was not associated with a significant
increased susceptibility for CD or UC. The GSTT1null genotype was
more often present in healthy controls compared with patients with
CD (OR 0.58; 95% CI 0.43–0.77). Although in UC patients the
GSTT1null genotype was more frequently seen, difference was not
significant (OR 1.14, 95% CI 0.81–1.61). The combination of
GSTM1null and GSTT1null genotypes was significantly seen more
in healthy controls compared with patients with CD (OR 0.44, 95%
CI 0.29–0.66). The association with the GSTT1null genotype and CD
and the combination of GSTT1null and GSTM1null had a P-value of
o0.001. This was still significant after correction for multiple testing
(Bonferroni’s correction).
Study characteristics of the meta-analyses
In total, 251 articles were identified. After removing duplicates and
screening for title and abstract, 11 articles remained.9–12,16–22 Three
studies20–22 were excluded because of Chinese language. One study
was excluded18 because of overlapping data with the results of our
case–control study. In the study of Karban et al.,10 the results of
Jewish, Arab moslems and Druze were merged. No studies had to be
excluded because of no full text availability. Furthermore, all studies
used genotyping methods that can detect the null genotype with
equivalent accuracy, except one study that used a genotype-validated
assay based on the GSTMu activity to identify patients with the null
genotype.
Results of the meta-analyses
No increased susceptibility was found for CD with the GSTM1null
(Figure 1) or GSTT1null genotype (Figure 2; OR 1.08, 95% CI 0.84–
Table 1 GST genotype distributions and OR with 95% CI of patients with CD and UC compared with controls in our case–control study
GST Genotype Predicted enzyme activity Controls (%) CD (%) OR (95% CI) UC (%) OR (95% CI)
GSTM1 *1*1/*1*0 High–intermediate 442 (45.5) 263 (47.6) Reference 116 (49.8) Reference
*0/*0 Absent 530 (54.5) 289 (52.4) 0.92 (0.74–1.13) 117 (50.2) 0.84 (0.63–1.12)
GSTT1 *1*1/*1*0 High–intermediate 769 (79.1) 479 (86.8) Reference 179 (76.8) Reference
*0/*0 Absent 203 (20.9) 73 (13.2) 0.58 (0.43–0.77)* 54 (23.2) 1.14 (0.81–1.61)
GSTM1 and GSTT1 *1*1/*1*0 and *1*1/*1*0 High–intermediate 850 (87.4) 490 (94) Reference 209 (89.7) Reference
*0/*0 and *0/*0 Absent 122 (12.6) 31 (6.0) 0.44 (0.29–0.66)* 24 (10.3) 0.80 (0.50–1.27)
Abbreviations: CD, Crohn’s disease; CI, confidence interval; GST, glutathione S-transferase; GSTM1, GST Mu; GSTT1, GST Theta; OR, odds ratio; UC, ulcerative colitis. ORs were calculated with
the genotypes with high–intermediate enzyme activity set as reference. *Po0.001.
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1.39 and 1.67, 95% CI 0.81–3.45, respectively). Also the combination
of both did not influence disease susceptibility (OR 1.30, 95% CI
0.41–4.14; Figure 3). Pooled analysis revealed an increased risk for UC
with the GSTT1null genotype (OR 2.27, 95% CI 1.31–3.92; Figure 4),
still significant after correction for multiple testing (P¼ 0.003).
For GSTM1null (OR 1.35, 95% CI 0.89–2.03) and the combination
of GSTT1null and GSTM1null (OR 1.99, 95% CI 0.65–6.12),
no significant influence on disease susceptibility was seen (see
Figures 5 and 6).
Publication bias
The funnel plot from the pooled analysis of GSTT1 in UC, the only
meta-analysis showing a significant effect, is depicted in Figure 7. This
meta-analysis included seven studies, and with the exception of one
outlier, the shape of the plot appears symmetrical.
DISCUSSION
The results of the current meta-analyses show a significantly increased
risk for UC, but not for CD, when bearing the GSTT1null genotype.
Figure 1 Forest plot of the association of the GSTM1null genotype with Crohn’s disease (CD). Effect of GSTM1null on the risk of CD (odds ratios (ORs) and
the 95% confidence intervals (CIs)) for each study is shown. The overall OR is 1.08 (95% CI 0.84–1.39). GSTM1null, homozygous presence of the
GSTM1*0 allele.
Figure 2 Forest plot of the association of the GSTT1null genotype with Crohn’s disease (CD). Effect of the GSTT1null genotype on the risk of CD (odds
ratios (ORs) and the 95% confidence intervals (CIs)) for each study is shown. The overall OR is 1.67 (95% CI 0.81–3.45). GSTT1null, homozygous
presence of the GSTT1*0 allele.
Figure 3 Association of the combination of GSTM1null and GSTT1null genotypes with Crohn’s disease (CD). Risk of CD (odds ratios (ORs) and the 95%
confidence intervals (CIs)) with both the GSTM1null and GSTT1null genotype versus all other variants is shown for each study. The overall OR is 1.30 (95%
CI 0.41–4.14). GSTM1null, homozygous presence of the GSTM1*0 allele; GSTT1null, homozygous presence of the GSTT1*0 allele.
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The GSTM1null genotype was not associated with CD or UC. It is
important to mention that the GSTM1null and GSTT1null poly-
morphisms were not analyzed in GWASs,1 because these
polymorphisms consist of large deletions rather than single-
nucleotide substitutions. With pooling data from case–control studies,
supplemented with our data, overall IBD patient numbers exceed
3200, which makes this meta-analyses the largest study so far.
The mechanism that absence of GSTT1 enzyme activity in
GSTT1null individuals contributes to the risk for UC might be
explained by the important role of this enzyme in the detoxification
of ROS,23 which may provide a trigger in the etiology of IBD.24,25
Also, in other inflammatory-driven diseases, such as asthma or type 2
diabetes mellitus, an increased susceptibility was found with the
GSTT1null genotype.26,27 In this meta-analyses, we showed that the
Figure 4 Forest plot of the association of the GSTT1null genotype with ulcerative colitis (UC). Effect of the GSTT1null genotype on the risk of UC (odds
ratios (ORs) and the 95% confidence intervals (CIs)) for each study is shown. The overall OR is 2.27 (95% CI 1.31–3.92). GSTT1null, homozygous
presence of the GSTT1*0 allele.
Figure 5 Forest plot of the association of the GSTM1null genotype with ulcerative colitis (UC). Effect of the GSTM1null genotype on the risk of UC (odds
ratios (ORs) and the 95% confidence intervals (CIs)) for each study is shown. The overall OR is 1.35 (95% CI 0.89–2.03). GSTM1null, homozygous
presence of the GSTM1*0 allele.
Figure 6 Association of the combination of GSTT1null and GSTM1null genotypes with ulcerative colitis (UC). Risk of UC (odds ratios (ORs) and
95% confidence intervals (CIs)) with both the GSTM1null and GSTT1null genotype versus all other variants is shown for each study. The overall OR is 1.99
(95% CI 0.65–6.12). GSTM1null, homozygous presence of the GSTM1*0 allele; GSTT1null, homozygous presence of the GSTT1*0 allele.
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GSTT1null genotype is associated with UC but not with CD. This
finding is not unique as 53 of the 163 loci associated with IBD were
disease specific.1
Although the studies conducted in Asia showed a larger association
between the GSTT1null genotype and UC than European studies, all
studies revealed an increased risk with only variation in the
magnitude. When the studies of Mittal et al.19 (OR 51.09, 95% CI
22.05–118.34) and Ye et al.9 (OR 2.06, 95% CI 1.53–2.77) were
excluded from the pooled analysis, leaving only Caucasians studies,
the GSTT1null genotype was still significantly seen more in UC
patients (OR 1.36, 95% CI 1.11–1.65). The increased, though not
significant susceptibility, for CD with the GSTT1null genotype is, to a
large extent, caused by the study of Mittal et al.19 with an OR of 47.8
(95% CI 10.5–218.4). The likely cause of this large OR is the low
number of patients (n¼ 20) with CD included, which is reflected by
the broad CI. When this study is excluded from the meta-analysis, the
OR is 1.08 (95% CI 0.59–2.00). Furthermore, in the forest plot of
GSTT1 in CD, a large difference was seen between the study of Ernst
et al.11 and our results, despite only a small geographical difference.
This might be caused by a relatively low number of healthy controls
with the GSTT1null genotype in the Danish study compared with our
study (13.2% vs 20.8%, respectively), where 19.7% is the average for
this area.8
Also, with the GSTM1null genotype, both the two studies
conducted in Asia (Mittal et al.19 and Ye et al.9) revealed the
highest association with IBD. However, overall no significant
influence was found. It might be that the loss of function of the
GSTM1 enzyme is compensated by other GST Mu classes, such as
GSTM2,28 this also explains why the combination of both GSTM1null
and GSTT1null did not have a synergistic effect on disease
susceptibility. Another explanation could be that the expression of
GSTM1 in the bowel is limited and therefore does not contribute in
the pathogenesis of IBD.2
The difference between the studies conducted in Asia and Europe
support the recent insights in differences in genetic variants associated
with IBD between the Caucasian and Asian race.29,30 Ng et al.29
showed that genetic variants of NOD2 frequently seen in Caucasian
IBD patients were rare in the Asian IBD population and vice versa.
Therefore it can be hypothesized that for Asians both GSTT1null and
GSTM1null may be involved in the etiology of UC, whereas in
Caucasians only the GSTT1null genotype is associated with UC. This
distinction might result from differences in life style, environmental
factors and the microbiome, requiring a different utilization of GST
subclasses. Ideally, subgroup analyses for different races are included;
however, absolute numbers of Asian IBD patients are insufficient for a
reliable estimation. This accentuates the need for larger studies in the
Asian IBD population exploring GSTM1null as well as GSTT1null
genotypes.
Single-nucleotide polymorphisms (SNPs) in the neighbor of the
deletion polymorphism may be in linkage disequilibrium and
subsequently might be used as a tag SNP. However, this method is
limited by the inter-population differences in the degree of linkage
disequilibrium. Most SNPs in linkage disequilibrium with GSTM1
and GSTT131 were not included in the most recent GWAS.1 This can
partly be explained by the fact that some of these tag SNPs such as
rs407257 lie in the deletion area.
As previous studies with comparable or smaller sample sizes were
able to show significant associations, we assumed to have sufficient
power with the patient numbers included in our case–control study.
In the present meta-analysis, heterogeneity between studies was
observed, which besides differences in race could have been originated
from differences in study design. For example, patient enrolment in
academic hospitals could be confounded by more severe disease
phenotypes included in academic hospitals. Also, the selection of
healthy controls might have an impact and could be a possible cause
for heterogeneity. Considering these potential differences, we used a
random-effect model for computing pooled ORs, with the knowledge
that in case of low heterogeneity results of a random model will
approach values of a fixed model, but preventing poorly substantiated
significant outcomes.32 The funnel plot of GSTT1null in UC contains
one outlier (the study of Mittal et al.19 with an OR of 51.09), though,
as mentioned above, with exclusion of this study still a significant
effect of GSTT1null and UC was observed. It has to be mentioned that
the number of studies published on this topic is limited, which makes
correct interpretation of the funnel plot difficult. Therefore influence
of publication bias should be considered, as studies showing a
significant influence of specific polymorphisms might be published
more often.33 Furthermore, the PCR techniques used in our case–
control study, and the other included studies, can only detect
homozygous (null) genotypes of the GSTM1*0 and GSTT1*0 alleles,
failing to detect heterozygous individuals. One study measured
GSTM1 enzyme activity instead of the GSTM1null genotype.12 We
decided to include this study in the meta-analyses as this method is
validated against the GSTM1 genotype and their findings showed that
50% of controls had no GSTM1 activity, which is in line with the
GSTM1null genotype frequency in that geographical area.8,34 In
addition, this method also lacks the capability to identify
GSTM1null heterozygotes
In conclusion, in this meta-analysis we show that the GSTT1null
genotype is associated with an increased the risk for UC but
not for CD.
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